IA
MAZE

IFP Advisors’s Maze Therapeutics MAZE Stock Holding History

IFP Advisors’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.79K Sell
328
-8,660
-96% -$227K ﹤0.01% 3405
2026
Q1 		$268K Buy
8,988
+5,474
+156% +$242K 0.01% 1247
2025
Q4 		$146K Buy
+3,514
New +$121K ﹤0.01% 1552
2025
Q3 		– Sell
-3
Closed -$37 – 4970
2025
Q2 		$37 Buy
+3
New +$31 ﹤0.01% 4818

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

IFP Advisors's MAZE Position: Q2 2026 in Review

IFP Advisors reduced its Maze Therapeutics (MAZE) stake by 96% in Q2 2026, selling an estimated $227K and leaving 328 shares worth $9.79K. The position accounts for ﹤0.01% of the portfolio, ranked #3405.

IFP Advisors first reported a position in MAZE in Q2 2025 and has held it in 4 quarters since. The position peaked at $268K in Q1 2026. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • IFP Advisors held 328 shares of Maze Therapeutics worth $9.79K as of Q2 2026.
  • IFP Advisors sold 8,660 Maze Therapeutics shares in Q2 2026, an estimated $227K.
  • Maze Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3405 holding.
  • IFP Advisors first reported a position in Maze Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • IFP Advisors's Maze Therapeutics position peaked at $268K in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.